Exactly! The issue is that any offer actually draws attention to NWBO and big pharma can’t take the chance that people will actually figure out what NWBO has. That would turn their products into second and third rate treatments that might not even be useful in the treatment of disease while still being debilitating. They are making too much money where they are at and want that money coming in all the way through patent expiration. The issue with an offer is Linda can shoot it down with the control she has and then you have a situation where NWBO gets publicity without big pharma getting what they want. Nope, bonifide offers will only come when individual situations dictate there is no other choice. Can’t wait for Flaskworks. Best wishes.
Market Data 
Markets 
AI
